Postinjury hyperfibrinogenemia compromises efficacy of heparin-based venous thromboembolism prophylaxis

Shock

Volumn 41, Issue 1, 2014, Pages 33-39

  Harr, Jeffrey N ^a   Moore, Ernest E ^a,b,c   Chin, Theresa L ^a   Ghasabyan, Arsen ^b,c   Gonzalez, Eduardo ^a   Wohlauer, Max V ^a   Sauaia, Angela ^a,c   Banerjee, Anirban ^c   Silliman, Christopher C ^a,b,d  

^a UNIVERSITY OF COLORADO   (United States)

^b DENVER HEALTH MEDICAL CENTER   (United States)

^c Trauma Research Center   (United States)

^d Bonfils Blood Center   (United States)

Author keywords

functional fibrinogen; hyperfibrinogenemia; Postinjury hypercoagulability; thromboelastography(TEG); trauma; venous thromboembolism (VTE

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; FIBRINOGEN; FIBRINOGEN CONCENTRATE; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; EMERGENCY HEALTH SERVICE; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HUMAN; HYPERCOAGULABILITY; IN VITRO STUDY; INJURY; INTENSIVE CARE UNIT; MALE; POSTINJURY HYPERFIBRINOGENEMIA; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; THROMBOELASTOGRAPHY; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOGEN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJURY SEVERITY SCORE; MALE; MIDDLE AGED; THROMBELASTOGRAPHY; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; WOUNDS AND INJURIES; YOUNG ADULT;

EID: 84891599456     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000067     Document Type: Article

References (34)

1. Shackford SR, Davis JW, Hollingsworth-Fridlund P, Brewer NS, Hoyt DB, Mackersie RC: Venous thromboembolism in patients with major trauma. Am J Surg 159(4):365-369, 1990.
2. Schultz DJ, Brasel KJ, Washington L, Goodman LR, Quickel RR, Lipchik RJ, Clever T, Weigelt J: Incidence of asymptomatic pulmonary embolism in moderately to severely injured trauma patients. J Trauma 56(4):727-731, 2004.
3. Toker S, Hak DJ, Morgan SJ: Deep vein thrombosis prophylaxis in trauma patients. Thrombosis 2011:505373, 2011.
4. Kudsk KA, Fabian TC, Baum S, Gold RE, Mangiante E, Voeller G: Silent deep vein thrombosis in immobilized multiple trauma patients. Am J Surg 158(6): 515-519, 1989.
5. Gearhart MM, Luchette FA, Proctor MC, Lutomski DM, Witsken C, James L, Davis K Jr, Johannigman JA, Hurst JM, Frame SB: The risk assessment profile score identifies trauma patients at risk for deep vein thrombosis. Surgery 128(4):631-640, 2000.
6. Velmahos GC, Toutouzas KG, Brown C, Vassiliu P, Gkiokas G, Rhee P: Thromboprophylaxis does not protect severely injured patients against pulmonary embolism. Am Surg 70(10):893-896, 2004.
7. Malinoski D, Jafari F, Ewing T, Ardary C, Conniff H, Baje M, Kong A, Lekawa ME, Dolich MO, Cinat ME, et al.: Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. J Trauma 68(4):874-880, 2010.
8. Haas CE, Nelsen JL, Raghavendran K, Mihalko W, Beres J, Ma Q, Forrest A: Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. J Trauma 59(6):1336-1343, 2005.
9. Park MS, Martini WZ, Dubick MA, Salinas J, Butenas S, Kheirabadi BS, Pusateri AE, Vos JA, Guymon CH, Wolf SE, et al.: Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time. J Trauma 67(2):266-275, 2009.
10. Van PY, Cho SD, Underwood SJ, Morris MS, Watters JM, Schreiber MA: Thrombelastography versus antiYfactor Xa levels in the assessment of prophylacticdose enoxaparin in critically ill patients. J Trauma 66(6):1509-1515, 2009.
11. Harr JN, Moore EE, Chin TL, Ghasabyan A, Gonzalez E, Wohlauer MV, Banerjee A, Silliman CC, Sauaia A: Platelets are dominant contributors to postinjury hypercoagulability. J Trauma Acute Care Surg 74(3):756-765, 2013.
12. Schochl H, Maegele M, Solomon C, Gorlinger K, Voelckel W: Early and individualized goal-directed therapy for trauma-induced coagulopathy. Scand J Trauma Resusc Emerg Med 20:15, 2012.
13. Harr JN, Moore EE, Ghasabyan A, Chin TL, Sauaia A, Banerjee A, Silliman CC: Functional fibrinogen assay indicates that fibrinogen is critical in correcting abnormal clot strength following trauma. SHOCK 39(1):45-49, 2013.
14. Machlus KR, Cardenas JC, Church FC, Wolberg AS: Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood 117(18):4953-4963, 2011.
15. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G: Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 311:501-505, 1984.
16. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG: Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 2:533-537, 1986.
17. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB: Fibrinogen and risk of cardiovascular disease the Framingham Study. JAMA 258:1183-1186, 1987.
18. Yarnell JW, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC: Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease the Caerphilly and Speedwell collaborative heart disease studies. Circulation 83:836-844, 1991.
19. Koenig W: Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 89:601-609, 2003.
20. The Emerging Risk Factors Collaboration: C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 367(14):1310-1320, 2012.
21. Maresca G, Di Blasio A, Marchioli R, Di Minno G: Measuring plasma fibrinogen to predict stroke and myocardial infarction. An update. Arterioscler Thromb Vasc Biol 19:1368-1377, 1999.
22. Endler G, Mannhalter C: Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis. Clin Chim Acta 330:31-55, 2003.
23. Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briet E, Vandenbroucke JP: Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case control study of plasma levels and DNA polymorphism the Leiden Thrombophilia Study (LETS). Thromb Haemost 71:719-722, 1994.
24. Borza DB, Morgan WT: Histidine-prolineYrich glycoprotein as a plasma pH sensor. Modulation of its interaction with glycosaminoglycans by ph and metals. J Biol Chem 273(10):5493-5499, 1998.
25. Bjork I, Olson ST, Sheffer RG, Shore JD: Binding of heparin to human high molecular weight kininogen. Biochemistry 28(3):1213-1221, 1998.
26. Hotchkiss KA, Chesterman CN, Hogg PJ: Inhibition of heparin activity in plasma by soluble fibrin: evidence for ternary thrombin-fibrin-heparin complex formation. Blood 84(2):498-503, 1994.
27. Yakovlev S, Gorlatov S, Ingham K, Medved L: Interaction of fibrin(ogen) with heparin: further characterization and localization of the heparin-binding site. Biochemistry 42(25):7709-7716, 2003.
28. Odrljin TM, Shainoff JR, Lawrence SO, Simpson-Haidaris PJ: Thrombin cleavage enhances exposure of a heparin binding domain in the N-terminus of the fibrin beta chain. Blood 88(6):2050-2061, 1996.
29. Young E, Cosmi B, Weitz J, Hirsh J: Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins. Thromb Haemost 70(4):625-630, 1993.
30. Lovely RS, Moaddel M, Farrell DH: Fibrinogen gamma¶ chain binds thrombin exosite II. J Thromb Haemost 1(1):124-131, 2003.
31. Hoffman M, Monroe DM: A cell-based model of hemostasis. Thromb Haemost 85(6):958-965, 2001.
32. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B: Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med 8(10):1175-1181, 2002.
33. Wohlauer MV, Moore EE, Thomas S, Sauaia A, Evans E, Harr J, Silliman CC, Ploplis V, Castellino FJ, Walsh M: Early platelet dysfunction: an unrecognized role in the acute coagulopathy of trauma. J Am Coll Surg 214(5):739-746, 2012.
34. Kutcher ME, Redick BJ, McCreery RC, Crane IM, Greenberg MD, Cachola LM, Nelson MF, Cohen MJ: Characterization of platelet dysfunction after trauma. J Trauma Acute Care Surg 73(1):13-19, 2012.